After studying a WHO document, Hyderabad-based vaccine producer Bharat Biotech will have its pre-submission meet with the World Health Organization (WHO) next Wednesday, i.e. on June 23, requesting the authorization of Covaxin, its India-made Covid-19 vaccine.
The pharma business has faced challenges in obtaining Covaxin authorized in some foreign nations because it lacks Phase-3 trial results, which is required for a WHO approval to ship the vaccine and include it in the much-coveted coronavirus “vaccine passport.”
Bharat Biotech previously informed ANI that Covaxin’s Phase-3 trial data would be made public in July, after which the firm would seek a full license of the Covid-19 vaccine in India.
Discussion about this post